Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
Gerratana L, Davis AA, Velimirovic M, Reduzzi C, Clifton K, Bucheit L, Hensing WL, Shah AN, Pivetta T, Dai CS, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Ma CX, Puglisi F, Bardia A, Cristofanilli M. Gerratana L, et al. Among authors: dai cs. JCO Precis Oncol. 2023 May;7:e2200531. doi: 10.1200/PO.22.00531. JCO Precis Oncol. 2023. PMID: 37141549 Free PMC article.
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
Davis AA, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Hensing WL, Bucheit L, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Gradishar WJ, Behdad A, Ma CX, Bardia A, Cristofanilli M. Davis AA, et al. Among authors: dai cs. EBioMedicine. 2022 Dec;86:104316. doi: 10.1016/j.ebiom.2022.104316. Epub 2022 Nov 1. EBioMedicine. 2022. PMID: 36332363 Free PMC article.
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Medford AJ, Oshry L, Boyraz B, Kiedrowski L, Menshikova S, Butusova A, Dai CS, Gogakos T, Keenan JC, Occhiogrosso RH, Ryan P, Lennerz JK, Spring LM, Moy B, Ellisen LW, Bardia A. Medford AJ, et al. Among authors: dai cs. Ther Adv Med Oncol. 2023 Jan 30;15:17588359231152844. doi: 10.1177/17588359231152844. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36743521 Free PMC article.
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.
Hensing WL, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Behdad A, Ma CX, Bardia A, Cristofanilli M, Davis AA. Hensing WL, et al. Among authors: dai cs. Clin Cancer Res. 2023 Aug 15;29(16):3092-3100. doi: 10.1158/1078-0432.CCR-22-3785. Clin Cancer Res. 2023. PMID: 37265453
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
Gerratana L, Davis AA, Velimirovic M, Clifton K, Hensing WL, Shah AN, Dai CS, Reduzzi C, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Puglisi F, Ma CX, Bardia A, Cristofanilli M. Gerratana L, et al. Among authors: dai cs. Breast Cancer Res. 2023 Oct 2;25(1):112. doi: 10.1186/s13058-023-01718-0. Breast Cancer Res. 2023. PMID: 37784176 Free PMC article.
21 results